LAG3 Expression in Triple Negative Breast Cancer

The Evaluation the Relationship Between LAG-3 Expression / Immune Checkpoint Protein Expression and Neoadjuvant Chemotherapy Plus Immune Checkpoint Inhibitor in Triple Negative Breast Cancer

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06259162

Enrollment

128

Registered

2024-02-14

Start date

2022-11-18

Completion date

2027-12-31

Last updated

2024-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune Checkpoint Inhibitor, Triple Negative Breast Cancer

Brief summary

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

Interventions

PROCEDURELAG-3 expression / immune checkpoint protein expression

Evaluate the tissue and blood before and after chemotherapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

* Planned neoadjuvant chemotherapy * Triple negative breast cancer

Exclusion criteria

* HER2-positive breast cancer * Hormone receptor positive breast cancer

Design outcomes

Primary

Measure	Time frame	Description
LAG-3 expression/immune checkpoint preotein expression	Before chemotherapy, 1 weeks & 3 weeks after chemotherapy, curative surgery	Relationship neoadjuvant chemotherapy plus immune checkpoint inhibitor

Countries

South Korea

Contacts

Primary ContactJi-Yeon Kim

jyeon25@skku.edu82-2-3410-3459

Backup ContactMee Ryung Hong

ring7629@naver.com82-2-2148-7147

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026